Metropolitan Life Insurance Co. NY held its stake in shares of CryoLife, Inc. (NYSE:CRY) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,366 shares of the medical equipment provider’s stock at the end of the first quarter. Metropolitan Life Insurance Co. NY’s holdings in CryoLife were worth $406,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of CRY. Elk Creek Partners LLC increased its stake in shares of CryoLife by 70.8% in the first quarter. Elk Creek Partners LLC now owns 496,917 shares of the medical equipment provider’s stock worth $8,274,000 after buying an additional 205,971 shares during the last quarter. Dialectic Capital Management LP bought a new stake in shares of CryoLife during the first quarter worth $2,238,000. Dimensional Fund Advisors LP increased its stake in shares of CryoLife by 5.7% in the first quarter. Dimensional Fund Advisors LP now owns 1,849,248 shares of the medical equipment provider’s stock worth $30,790,000 after buying an additional 100,125 shares during the last quarter. Royce & Associates LP increased its stake in shares of CryoLife by 32.5% in the first quarter. Royce & Associates LP now owns 395,700 shares of the medical equipment provider’s stock worth $6,588,000 after buying an additional 97,000 shares during the last quarter. Finally, MARSHALL WACE ASIA Ltd bought a new stake in shares of CryoLife during the first quarter worth $1,035,000. 69.22% of the stock is currently owned by institutional investors.

CryoLife, Inc. (NYSE CRY) remained flat at $19.10 during midday trading on Thursday. 5,604 shares of the stock were exchanged. The firm has a market cap of $638.82 million, a price-to-earnings ratio of 57.88 and a beta of 0.97. The stock has a 50-day moving average price of $19.24 and a 200-day moving average price of $17.96. CryoLife, Inc. has a 12-month low of $14.02 and a 12-month high of $20.30.

CryoLife (NYSE:CRY) last released its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.10 by $0.02. The business had revenue of $47.80 million during the quarter, compared to analysts’ expectations of $47.02 million. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.13 EPS. On average, analysts predict that CryoLife, Inc. will post $0.43 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/17/cryolife-inc-cry-position-held-by-metropolitan-life-insurance-co-ny.html.

A number of equities research analysts recently weighed in on CRY shares. Zacks Investment Research raised CryoLife from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a research report on Thursday, June 8th. Northland Securities reaffirmed a “buy” rating and set a $23.50 price objective on shares of CryoLife in a research report on Friday, April 28th. Finally, BidaskClub downgraded CryoLife from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $22.00.

In related news, VP Amy Horton sold 9,577 shares of the company’s stock in a transaction dated Tuesday, June 27th. The stock was sold at an average price of $20.00, for a total value of $191,540.00. Following the completion of the sale, the vice president now directly owns 112,282 shares of the company’s stock, valued at approximately $2,245,640. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 6.00% of the company’s stock.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoLife, Inc. (NYSE:CRY).

Institutional Ownership by Quarter for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.